Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Cryo Cell International's Cost of Revenue fell 1526.11% to $1.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was $7.3 million, marking a year-over-year decrease of 1166.72%. This contributed to the annual value of $7.9 million for FY2024, which is 527.64% down from last year.
  • Latest data reveals that Cryo Cell International reported Cost of Revenue of $1.8 million as of Q3 2025, which was down 1526.11% from $1.9 million recorded in Q2 2025.
  • Cryo Cell International's Cost of Revenue's 5-year high stood at $2.5 million during Q3 2021, with a 5-year trough of $1.6 million in Q4 2024.
  • In the last 5 years, Cryo Cell International's Cost of Revenue had a median value of $2.1 million in 2022 and averaged $2.1 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 1961.32% in 2021, then soared by 452.27% in 2022.
  • Over the past 5 years, Cryo Cell International's Cost of Revenue (Quarter) stood at $2.3 million in 2021, then decreased by 6.84% to $2.1 million in 2022, then dropped by 5.38% to $2.0 million in 2023, then fell by 19.13% to $1.6 million in 2024, then rose by 10.06% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.9 million for Q2 2025, and $2.0 million during Q1 2025.